Agilent Technologies, Inc.
As of Fiscal Year 2025 (ended October 31, 2025)
Key KPIs at a Glance
| Metric | Value |
|---|---|
| Total revenue (FY2025) | $6.948 billion, up 6.7% year-over-year (up 4.9% on a core basis) |
| GAAP net income (FY2025) | $1.303 billion, up 3% year-over-year |
| Non-GAAP net income (FY2025) | $1.592 billion, up 6% year-over-year |
| GAAP diluted EPS (FY2025) | $4.57, up 3% year-over-year |
| Non-GAAP diluted EPS (FY2025) | $5.59, up 6% year-over-year |
| GAAP operating income (FY2025) | $1.479 billion (21.3% of revenue) |
| R&D expense (FY2025) | $455 million, approximately 6.5% of revenue |
| Q4 FY2025 revenue | $1.861 billion, up 9.4% year-over-year (up 7.2% on a core basis) |
| Employees (approximate, FY2025) | Approximately 18,000 employees worldwide |
| FY2026 revenue guidance | $7.3-$7.4 billion (initiated with Q4 FY2025 results) |
Sources: All figures are company-disclosed, from Agilent Technologies' Q4/FY2025 earnings release (press release dated November 24, 2025; SEC Form 8-K, Exhibit 99.1) and prior-year 8-K press releases for FY2021-FY2024 history. Starting in fiscal 2025, Agilent realigned into three reporting segments -- Life Sciences and Diagnostics Markets Group (LDG), Agilent CrossLab Group (ACG), and Applied Markets Group (AMG) -- replacing the prior Life Sciences and Applied Markets Group (LSAG) / Diagnostics and Genomics Group (DGG) / Agilent CrossLab Group (ACG) structure; FY2024 segment figures below are as recast by Agilent for comparability. No third-party estimates are used; no credibly-sourced, specifically-dated market-share estimate for Agilent's core markets was found in a reasonable search, so that widget is omitted per instructions.